Table 1.
Cellular properties before and after HFS
| Control | SCH 23390 | Remoxipride | AMPT | AMPT + SKF 38393 | |
|---|---|---|---|---|---|
| n | 6 | 5 | 4 | 6 | 5 |
| Membrane potential, mV | |||||
| Pre | −95.3 ± 4.6 | −95.4 ± 2.2 | −96.5 ± 1.2 | −94.5 ± 1.0 | −94.2 ± 1.5 |
| Post | −97.0 ± 3.1 | −93.6 ± 3.3 | −98.5 ± 1.3 | −93.0 ± 1.5 | −96.2 ± 1.9 |
| Input resistance, MΩ | |||||
| Pre | 36.5 ± 8.8 | 44.7 ± 4.6 | 56.5 ± 17.6 | 50.4 ± 9.9 | 44.5 ± 3.1 |
| Post | 33.6 ± 6.0 | 41.7 ± 0.9 | 59.9 ± 16.8 | 42.5 ± 15.4 | 37.1 ± 2.4 |
| Firing threshold, mV | |||||
| Pre | −53.7 ± 0.2 | −53.6 ± 2.8 | −53.2 ± 5.1 | −58.2 ± 1.1 | −49.9 ± 3.1 |
| Post | −50.5 ± 2.0 | −52.5 ± 2.5 | −53.7 ± 3.5 | −57.0 ± 1.5 | −48.3 ± 6.1 |
| Action potential amplitude, mV | |||||
| Pre | 78.0 ± 6.5 | 77.4 ± 2.1 | 75.9 ± 1.4 | 76.9 ± 3.2 | 76.5 ± 2.5 |
| Post | 68.6 ± 9.3 | 76.4 ± 4.3 | 73.5 ± 1.8 | 78.7 ± 2.0 | 79.7 ± 2.4 |
| Action potential duration, ms | |||||
| Pre | 0.7 ± 0.1 | 0.6 ± 0.1 | 0.7 ± 0.1 | 0.9 ± 0.0 | 0.7 ± 0.0 |
| Post | 0.7 ± 0.2 | 0.7 ± 0.1 | 0.8 ± 0.0 | 0.8 ± 0.0 | 0.7 ± 0.0 |
| AHP amplitude, mV | |||||
| Pre | 14.1 ± 1.7 | 14.5 ± 1.7 | 14.0 ± 0.3 | 12.0 ± 0.5 | 13.5 ± 0.6 |
| Post | 15.4 ± 1.5 | 13.6 ± 1.3 | 11.2 ± 1.0 | 13.9 ± 0.5 | 16.1 ± 0.9 |
| EPSP slope, mV/ms | |||||
| Pre | 6.8 ± 1.0 | 5.3 ± 1.2 | 7.0 ± 0.4 | 5.9 ± 0.7 | 7.2 ± 1.2 |
| Post | 7.7 ± 1.0 | 5.0 ± 1.0 | 8.7 ± 0.4 | 5.2 ± 0.4 | 10.7 ± 1.3 |
| EPSP peak, mV | |||||
| Pre | 16.0 ± 2.0 | 16.7 ± 3.3 | 19.2 ± 1.6 | 17.7 ± 1.5 | 18.0 ± 2.0 |
| Post | 19.4 ± 2.2 | 16.5 ± 3.5 | 23.1 ± 1.2 | 16.0 ± 1.6 | 22.2 ± 2.8 |
-
Cellular properties were measured routinely 10 min before high-frequency stimulation (HFS Pre) and 20 min after HFS (Post). There were no significant differences in cellular properties between treatment groups (2-tailed t-test) or within groups before and after HFS (paired t-test). Values are means ± SE. AMPT, alpha-methyl paratyrosine; AHP, afterhyperpolarization; EPSP, excitatory postsynaptic potential.